The FDA declared that shortages of tirzepatide and semaglutide had ended when the drug manufacturers stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies, the agency said when each shortage was declared to be over
7 Side-effect profiles look broadly comparable, with gastrointestinal side effects most common on both drugs
You might experience nausea, bloating or changes in digestion, especially early on
Daily use should follow a doctor's specific instructions
When women have hot flashes, their heart rates can rise, people have thought of palpitations as being caused by hot flashes or associated with them, Carpenter says
Some platforms also provide pharmacy discounts or generic alternatives that meet FDA guidelines